Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period [Phase 3]

View source ↗

Summary

Phase 3 clinical trial to evaluate the efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency, including a 5-year extension peri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia
• Pyruvate Kinase Deficiency

Drugs mentioned

• Mitapivat (mitapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING